异常的MLH1细胞质局部化标志着细胞群种植乳腺癌复发的种子
Aloran Mazumder1,2, Jerry Dewitt1,2, Elena Oropeza1
1Department of Biology, San Diego State University, San Diego, CA, USA.
Nature communications
|December 10, 2025
概括
在雌激素受体阳性乳腺癌中MLH1的细胞质局部化驱动内分泌治疗耐药性. 这一发现表明CDK4/6抑制剂可能有利于患有这种特定MLH1失调的患者.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞生物学 细胞生物学
背景情况:
- 雌激素受体阳性 (ER+) 乳腺癌是癌症死亡的主要原因,通常是由于复发性,耐治疗性疾病.
- 丧失MLH1功能有助于通过破坏细胞循环控制来抵抗雌激素向疗法.
- 异常的MLH1局部化,而不仅仅是表达水平,可以影响治疗反应.
研究的目的:
- 研究MLH1蛋白局部化在ER+乳腺癌内分泌疗法耐药性中的作用.
- 确定细胞质MLH1局部化是否有助于雌激素独立生长和耐药性.
- 评估针对细胞质MLH1.1.的瘤中的CDK4/6向的潜力.
主要方法:
- 在ER+乳腺癌细胞和患者样本中分析MLH1蛋白位址 (核与细胞质).
- 在具有不同MLH1局部化模式的细胞中评估细胞周期进展和雌激素依赖性.
- 在核与细胞质MLH1.1.的模型中对CDK4/6抑制剂的治疗反应评估.
主要成果:
- 异常的MLH1细胞质局部化,即使表达丰富,通过使雌激素独立生长,促进内分泌疗法耐药性.
- 细胞质MLH1的细胞无法有效地阻止细胞循环响应内分泌疗法,增加对CDK4/6.6的依赖.
- 与核MLH1.1的细胞相比,CDK4/6抑制剂在表现出细胞质MLH1局部化的细胞中显示出显著的瘤回归.
- 细胞质MLH1局部化观察到约11%的ER+乳腺癌患者.
结论:
- 细胞质MLH1局部化是一种新的机制,有助于ER+乳腺癌的内分泌治疗耐药性.
- 这种特定的MLH1失调产生了对CDK4/6活性的依赖,使这些抑制剂成为潜在的治疗策略.
- 将MLH1细胞质局部化的评估整合到诊断中,可以确定一组可能受益于CDK4/6抑制剂的患者.
相关概念视频
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
Cancer Stem Cells and Tumor Maintenance
5.8K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Induced Pluripotent Stem Cells
5.3K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.3K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Metastasis
6.3K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.3K
Cancers Originate from Somatic Mutations in a Single Cell
14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K


